Single-Fraction Radiotherapy for CD30(+) Lymphoproliferative Disorders.
OBJECTIVE
CD30(+) lymphoproliferative disorder is a rare variant of cutaneous T-cell lymphoma. Sustained complete response following first-line treatments is rare. This retrospective review evaluates the response of refractory or recurrent lesions to palliative radiation therapy.


METHODS
The records of 6 patients with 12 lesions, treated with radiation therapy, were reviewed. All patients received previous first-line treatments. Patients with clinical and pathological evidence of symptomatic CD30(+) lymphoproliferative disorder, with no history of other cutaneous T-cell lymphoma variants, and with no prior radiation therapy to the index site were included.


RESULTS
The median age of patients was 50.5 years (range, 15-83 years). Median size of the treated lesions was 2.5 cm (range, 2-7 cm). Four sites were treated with a single fraction of 750-800 cGy (n = 3) and 8 sites were treated with 4000-4500 cGy in 200-250 cGy fractions (n = 3). Radiation therapy was administered with electrons and bolus. Median follow-up was 113 months (range, 16-147 months). For all sites, there was 100% complete response with acute grade 1-2 dermatitis.


CONCLUSIONS
For recurrent and symptomatic radiation-naïve CD30(+) lymphoproliferative disorder lesions, palliative radiation therapy shows excellent response. A single fraction of 750-800 cGy is as effective as a multifractionated course and more convenient.
Department of Radiation Oncology, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA.
Michelle S
MS
Gentile
Department of Dermatology, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA.
Maria Estela
ME
Martinez-Escala
Department of Radiation Oncology, Loyola University, Chicago, IL 60153, USA.
Tarita O
TO
Thomas
Department of Dermatology, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA.
Joan
J
Guitart
Division of Medical Oncology, Department of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA.
Steven
S
Rosen
Division of Medical Oncology, Department of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA.
Timothy
T
Kuzel
Department of Radiation Oncology, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA.
Bharat B
BB
Mittal
D000293:Adolescent; D000328:Adult; D000369:Aged, 80 and over; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D017730:Ki-1 Antigen / Q000378:metabolism*; D008232:Lymphoproliferative Disorders / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012867:Skin / Q000737:chemistry / Q000166:cytology / Q000473:pathology
D017730:Ki-1 Antigen